intellia
therapeutics
announces
third
quarter
financial
results
track
dose
first
patient
treatment
transthyretin
amyloidosis
attr
following
regulatory
authorization
initiate
phase
clinical
trial
anticipates
submitting
ind
lead
cell
therapy
treatment
acute
myeloid
leukemia
aml
expects
submit
ind
treatment
hereditary
angioedema
hae
ended
quarter
strong
cash
position
million
cambridge
globe
newswire
intellia
therapeutics
nasdaq
ntla
leading
genome
editing
company
focused
developing
curative
therapeutics
using
crispr
technology
vivo
ex
vivo
today
reported
operational
highlights
financial
results
third
quarter
ended
september
pleased
recent
regulatory
authorization
begin
phase
study
keeps
us
track
dose
first
patient
important
step
toward
improving
lives
attr
patients
potentially
curative
treatment
marks
transition
company
advancing
major
milestone
field
genome
editing
first
clinical
trial
systemically
delivered
crispr
therapy
said
intellia
president
chief
executive
officer
john
leonard
parallel
progressing
treatment
aml
hae
respectively
ind
equivalent
regulatory
submission
next
year
also
continue
develop
innovative
capabilities
across
platform
based
nobel
crispr
technology
generate
next
wave
therapeutic
third
quarter
recent
operational
highlights
attr
program
intellia
recently
announced
authorization
clinical
trial
application
cta
united
kingdom
medicines
healthcare
products
regulatory
agency
mhra
initiate
clinical
trial
investigational
therapy
development
treatment
clinical
manifestations
attr
applying
company
vivo
liver
gene
knockout
technology
allows
possibility
lifelong
transthyretin
ttr
protein
reduction
single
course
treatment
intellia
study
evaluate
adults
hereditary
attr
polyneuropathy
phase
study
open
label
study
assess
safety
tolerability
pharmacokinetics
pharmacodynamics
include
measurement
serum
ttr
levels
following
single
intravenous
infusion
intellia
track
dose
first
patient
end
subject
impact
pandemic
submitting
additional
regulatory
applications
countries
part
ongoing
global
development
strategy
safety
optimal
dose
determined
study
intellia
intends
evaluate
broader
attr
patient
population
polyneuropathy
cardiomyopathy
patients
part
agreement
intellia
lead
development
commercialization
party
regeneron
pharmaceuticals
regeneron
intellia
recently
announced
authorization
clinical
trial
application
cta
united
kingdom
medicines
healthcare
products
regulatory
agency
mhra
initiate
clinical
trial
investigational
therapy
development
treatment
clinical
manifestations
attr
applying
company
vivo
liver
gene
knockout
technology
allows
possibility
lifelong
transthyretin
ttr
protein
reduction
single
course
treatment
intellia
study
evaluate
adults
hereditary
attr
polyneuropathy
phase
study
open
label
study
assess
safety
tolerability
pharmacokinetics
pharmacodynamics
include
measurement
serum
ttr
levels
following
single
intravenous
infusion
intellia
track
dose
first
patient
end
subject
impact
pandemic
submitting
additional
regulatory
applications
countries
part
ongoing
global
development
strategy
safety
optimal
dose
determined
study
intellia
intends
evaluate
broader
attr
patient
population
polyneuropathy
cardiomyopathy
patients
part
agreement
intellia
lead
development
commercialization
party
regeneron
pharmaceuticals
regeneron
aml
program
wholly
owned
cell
receptor
tcr
cell
therapy
development
candidate
targeting
wilms
tumor
antigen
treatment
aml
company
seeks
develop
broadly
applicable
treatment
aml
patients
regardless
mutational
subtypes
cancer
intellia
continues
advance
investigational
new
drug
application
ind
activities
remains
track
submit
ind
first
half
upcoming
nd
american
society
hematology
ash
annual
meeting
taking
place
virtually
december
company
present
new
preclinical
results
support
showing
high
activity
lead
therapy
mouse
model
aml
preclinical
data
also
highlight
advantages
proprietary
cell
engineering
process
produce
multiple
highly
efficient
sequential
edits
cells
superior
function
minimal
translocations
compared
results
standard
cell
engineering
approaches
additional
efforts
underway
evaluate
potential
use
treat
solid
tumors
wholly
owned
cell
receptor
tcr
cell
therapy
development
candidate
targeting
wilms
tumor
antigen
treatment
aml
company
seeks
develop
broadly
applicable
treatment
aml
patients
regardless
mutational
subtypes
cancer
intellia
continues
advance
investigational
new
drug
application
ind
activities
remains
track
submit
ind
first
half
upcoming
american
society
hematology
ash
annual
meeting
taking
place
virtually
december
company
present
new
preclinical
results
support
showing
high
activity
lead
therapy
mouse
model
aml
preclinical
data
also
highlight
advantages
proprietary
cell
engineering
process
produce
multiple
highly
efficient
sequential
edits
cells
superior
function
minimal
translocations
compared
results
standard
cell
engineering
approaches
additional
efforts
underway
evaluate
potential
use
treat
solid
tumors
hae
program
wholly
owned
vivo
development
candidate
treatment
hae
today
intellia
announced
results
completed
primate
nhp
study
lead
lipid
nanoparticle
lnp
formulation
following
single
dose
knockout
prekallikrein
gene
resulted
therapeutically
relevant
reduction
serum
kallikrein
protein
levels
activity
building
intellia
modular
lnp
delivery
system
designed
knock
gene
liver
single
course
treatment
approach
expected
prevent
improperly
regulated
bradykinin
production
therefore
reduce
hae
attacks
third
quarter
company
initiated
good
laboratory
practices
glp
toxicology
studies
preparation
ind
submission
remains
track
second
half
wholly
owned
vivo
development
candidate
treatment
hae
today
intellia
announced
results
completed
primate
nhp
study
lead
lipid
nanoparticle
lnp
formulation
following
single
dose
knockout
prekallikrein
gene
resulted
therapeutically
relevant
reduction
serum
kallikrein
protein
levels
activity
building
intellia
modular
lnp
delivery
system
designed
knock
gene
liver
single
course
treatment
approach
expected
prevent
improperly
regulated
bradykinin
production
therefore
reduce
hae
attacks
third
quarter
company
initiated
good
laboratory
practices
glp
toxicology
studies
preparation
ind
submission
remains
track
second
half
modular
platform
intellia
continues
make
significant
progress
across
platform
technologies
broadening
vivo
ex
vivo
application
genome
editing
includes
developing
innovative
crispr
targeted
transgene
insertion
allogeneic
cell
solutions
th
annual
meeting
oligonucleotide
therapeutics
society
held
september
intellia
presented
new
data
highlighting
potential
develop
therapies
may
lifelong
effect
variety
genetic
diseases
data
showed
persistence
vivo
knockout
insertion
crispr
edits
corresponding
durability
effect
following
partial
hepatectomy
phx
liver
regrowth
murine
model
unlike
traditional
gene
therapy
significant
loss
transgene
expression
observed
insertion
phx
model
intellia
targeted
gene
insertion
approach
yielded
durable
edits
significant
loss
expression
model
intellia
regeneron
potential
hemophilia
b
crispr
treatments
using
jointly
developed
insertion
capabilities
intellia
also
continuing
develop
proprietary
platform
advance
programs
intellia
continues
make
significant
progress
across
platform
technologies
broadening
vivo
ex
vivo
application
genome
editing
includes
developing
innovative
crispr
targeted
transgene
insertion
allogeneic
cell
solutions
annual
meeting
oligonucleotide
therapeutics
society
held
september
intellia
presented
new
data
highlighting
potential
develop
therapies
may
lifelong
effect
variety
genetic
diseases
data
showed
persistence
vivo
knockout
insertion
crispr
edits
corresponding
durability
effect
following
partial
hepatectomy
phx
liver
regrowth
murine
model
unlike
traditional
gene
therapy
significant
loss
transgene
expression
observed
insertion
phx
model
intellia
targeted
gene
insertion
approach
yielded
durable
edits
significant
loss
expression
model
intellia
regeneron
potential
hemophilia
b
crispr
treatments
using
jointly
developed
insertion
capabilities
intellia
also
continuing
develop
proprietary
platform
advance
programs
board
directors
october
intellia
appointed
john
crowley
board
directors
crowley
chairman
chief
executive
officer
amicus
therapeutics
leader
biotech
pharmaceuticals
visionary
advocate
advancement
treatments
people
living
rare
diseases
october
intellia
appointed
john
crowley
board
directors
crowley
chairman
chief
executive
officer
amicus
therapeutics
leader
biotech
pharmaceuticals
visionary
advocate
advancement
treatments
people
living
rare
diseases
scientific
awarded
nobel
prize
jennifer
doudna
one
intellia
scientific
awarded
nobel
prize
chemistry
inventing
revolutionary
crispr
genome
editing
technology
doudna
shares
award
research
collaborator
emmanuelle
charpentier
upcoming
events
company
participate
following
events
fourth
quarter
credit
suisse
healthcare
conference
november
virtual
barclays
gene
editing
therapy
summit
november
virtual
ash
annual
meeting
december
virtual
upcoming
milestones
company
set
forth
following
pipeline
progression
attr
dose
first
patient
phase
study
aml
submit
ind
hae
submit
ind
third
quarter
financial
results
cash
position
cash
cash
equivalents
marketable
securities
million
september
compared
million
december
increase
driven
net
proceeds
million
june
public
offering
million
upfront
payment
regeneron
collaboration
expansion
included
million
equity
investment
million
net
equity
proceeds
raised
company
market
atm
agreement
million
funding
received
regeneron
novartis
collaborations
million
proceeds
stock
plans
increases
offset
part
cash
used
fund
operations
approximately
million
cash
cash
equivalents
marketable
securities
million
september
compared
million
december
increase
driven
net
proceeds
million
june
public
offering
million
upfront
payment
regeneron
collaboration
expansion
included
million
equity
investment
million
net
equity
proceeds
raised
company
market
atm
agreement
million
funding
received
regeneron
novartis
collaborations
million
proceeds
stock
plans
increases
offset
part
cash
used
fund
operations
approximately
million
collaboration
revenue
collaboration
revenue
increased
million
million
third
quarter
compared
million
third
quarter
increase
mainly
driven
million
amount
recognized
transfer
control
license
develop
factor
viii
target
hemophilia
associated
extension
regeneron
collaboration
collaboration
revenue
increased
million
million
third
quarter
compared
million
third
quarter
increase
mainly
driven
million
amount
recognized
transfer
control
license
develop
factor
viii
target
hemophilia
associated
extension
regeneron
collaboration
r
expenses
research
development
expenses
increased
approximately
million
million
third
quarter
compared
million
third
quarter
increase
primarily
driven
advancement
lead
programs
research
personnel
growth
support
programs
expansion
development
organization
research
development
expenses
increased
approximately
million
million
third
quarter
compared
million
third
quarter
increase
primarily
driven
advancement
lead
programs
research
personnel
growth
support
programs
expansion
development
organization
g
expenses
general
administrative
expenses
increased
approximately
million
million
third
quarter
compared
million
third
quarter
increase
primarily
related
employee
related
expenses
including
compensation
million
general
administrative
expenses
increased
approximately
million
million
third
quarter
compared
million
third
quarter
increase
primarily
related
employee
related
expenses
including
compensation
million
net
loss
company
net
loss
million
third
quarter
compared
million
third
quarter
financial
guidance
intellia
expects
cash
cash
equivalents
marketable
securities
september
enable
company
fund
anticipated
operating
expenses
capital
expenditure
requirements
least
next
months
expectation
excludes
strategic
use
capital
currently
company
planning
assumptions
conference
call
discuss
third
quarter
earnings
company
discuss
results
conference
call
today
november
et
join
call
callers
dial
international
callers
dial
approximately
five
minutes
call
participants
ask
connected
intellia
therapeutics
conference
call
replay
call
available
events
presentations
page
investors
media
section
intellia
website
beginning
november
et
intellia
therapeutics
intellia
therapeutics
leading
genome
editing
company
focused
development
proprietary
potentially
curative
therapeutics
using
crispr
system
intellia
believes
crispr
technology
potential
transform
medicine
producing
therapeutics
permanently
edit
correct
genes
human
body
single
treatment
course
creating
enhanced
engineered
cells
treat
oncological
immunological
diseases
intellia
combination
deep
scientific
technical
clinical
development
experience
along
leading
intellectual
property
portfolio
puts
unique
position
unlock
broad
therapeutic
applications
crispr
technology
create
new
classes
therapeutic
products
learn
intellia
therapeutics
crispr
follow
us
twitter
intelliatweets
statements
press
release
contains
statements
intellia
therapeutics
intellia
within
meaning
private
securities
litigation
reform
act
statements
include
limited
express
implied
statements
regarding
intellia
beliefs
expectations
regarding
able
initiate
clinical
studies
treatment
transthyretin
amyloidosis
attr
pursuant
clinical
trial
applications
cta
including
dosing
first
patient
end
submitting
similar
regulatory
applications
countries
plans
submit
investigational
new
drug
ind
application
similar
clinical
trial
application
first
cell
receptor
tcr
engineered
cell
therapy
development
candidate
acute
myeloid
leukemia
aml
program
first
half
plans
submit
ind
similar
clinical
trial
application
hereditary
angioedema
hae
program
second
half
plans
advance
complete
preclinical
studies
including
primate
studies
hae
programs
animal
studies
supporting
vivo
ex
vivo
programs
including
aml
program
development
proprietary
lnp
aav
hybrid
delivery
system
well
modular
platform
advance
complex
genome
editing
capabilities
gene
insertion
development
proprietary
cell
engineering
process
multiple
sequential
editing
presentation
additional
data
upcoming
scientific
conferences
preclinical
data
advancement
expansion
crispr
technology
develop
human
therapeutic
products
well
ability
maintain
expand
related
intellectual
property
portfolio
ability
demonstrate
platform
modularity
replicate
apply
results
achieved
preclinical
studies
including
attr
aml
hae
programs
future
studies
including
human
clinical
trials
expectations
potential
impact
coronavirus
disease
pandemic
strategy
future
operations
timing
clinical
trials
ind
submissions
ability
develop
vivo
ex
vivo
cell
therapeutics
types
targeting
aml
particular
using
crispr
technology
ability
optimize
impact
collaborations
development
programs
including
limited
collaborations
novartis
institutes
biomedical
research
novartis
regeneron
pharmaceuticals
regeneron
including
programs
hemophilia
hemophilia
b
statements
regarding
timing
regulatory
filings
clinical
trial
execution
including
dosing
patients
regarding
development
programs
potential
commercial
opportunities
including
value
market
product
candidates
expectations
regarding
use
capital
financial
results
ability
fund
operations
least
next
months
statements
press
release
based
management
current
expectations
beliefs
future
events
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
set
forth
implied
statements
risks
uncertainties
include
limited
risks
related
intellia
ability
protect
maintain
intellectual
property
position
risks
related
intellia
relationship
third
parties
including
licensors
licensees
risks
related
ability
licensors
protect
maintain
intellectual
property
position
uncertainties
related
regulatory
agencies
evaluation
regulatory
filings
information
related
product
candidates
uncertainties
related
authorization
initiation
conduct
studies
development
requirements
product
candidates
risk
one
intellia
product
candidates
including
successfully
developed
commercialized
risk
results
preclinical
studies
clinical
studies
predictive
future
results
connection
future
studies
risk
intellia
collaborations
novartis
regeneron
ex
vivo
collaborations
continue
successful
discussion
risks
uncertainties
important
factors
could
cause
intellia
actual
results
differ
contained
statements
see
section
entitled
risk
factors
intellia
recent
annual
report
form
well
discussions
potential
risks
uncertainties
important
factors
intellia
filings
securities
exchange
commission
sec
information
press
release
date
release
intellia
undertakes
duty
update
information
unless
required
law
intellia
therapeutics
consolidated
statements
operations
unaudited
amounts
thousands
except
per
share
data
three
months
ended
september
nine
months
ended
september
collaboration
revenue
operating
expenses
research
development
general
administrative
total
operating
expenses
operating
loss
interest
income
net
loss
net
loss
per
share
basic
diluted
weighted
average
shares
outstanding
basic
diluted
intellia
therapeutics
consolidated
balance
sheet
data
unaudited
amounts
thousands
september
december
cash
cash
equivalents
marketable
securities
total
assets
total
liabilities
total
stockholders
equity
intellia
contacts
investors
lina
li
associate
director
investor
relations
media
jennifer
mound
smoter
senior
vice
president
external
affairs
communications
